Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk

Jay L Goldstein, David J Whellan, James M Scheiman, Byron L Cryer, Glenn M Eisen, Angel Lanas, John G Fort, Jay L Goldstein, David J Whellan, James M Scheiman, Byron L Cryer, Glenn M Eisen, Angel Lanas, John G Fort

Abstract

Introduction: In two, 6-month, randomized, double-blind Phase 3 trials, PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) compared to aspirin alone was associated with fewer endoscopic gastric and duodenal ulcers in patients requiring aspirin therapy for secondary cardiovascular disease (CVD) prevention who were at risk for upper gastrointestinal (UGI) events.

Aims: In this 12-month, open-label, multicenter Phase 3 study, we evaluated the long-term cardiovascular and gastrointestinal safety of PA32540 in subjects who were taking aspirin 325 mg daily for ≥ 3 months for secondary CVD prevention and were at risk for aspirin-associated UGI events. Enrolled subjects received PA32540 once daily for up to 12 months and were assessed at baseline, month 1, month 6, and month 12.

Results: The overall safety population consisted of 379 subjects, and 290 subjects (76%) were on PA32540 for ≥ 348 days (12-month completers). Adverse events (AEs) caused study withdrawal in 13.5% of subjects, most commonly gastroesophageal reflux disease (1.1%). Treatment-emergent AEs occurred in 76% of the safety population (11% treatment-related) and 73% of 12-month completers (8% treatment-related). The most common treatment-related AE was dyspepsia (2%). One subject had a gastric ulcer observed on for-cause endoscopy. There were five cases of adjudicated nonfatal myocardial infarction, one nonfatal stroke, and one cardiovascular death, but none considered treatment-related.

Conclusions: Long-term treatment with PA32540 once daily for up to 12 months in subjects at risk for aspirin-associated UGI events is not associated with any new or unexpected safety events.

Trial registration: ClinicalTrials.gov NCT00995410.

Keywords: Aspirin; Dyspepsia; Gastroesophageal reflux disease; Gastrointestinal; Omeprazole; Secondary cardiovascular disease prevention.

© 2016 The Authors. Cardiovascular Therapeutics Published by John Wiley & Sons Ltd.

References

    1. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011;58:2432–2446. Erratum in: J Am Coll Cardiol 2015;65:1495.
    1. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non‐ST‐elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e663–e828. Erratum in: Circulation 2013;127:e863–e864.
    1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160–2236. Erratum in: Stroke 2015;46:e54.
    1. Lanas Á, Carrera‐Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti‐inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015;13:906–912.
    1. Kawasaki K, Kurahara K, Yanai S, Kochi S, Fuchigami T, Matsumoto T. Low‐dose aspirin and non‐steroidal anti‐inflammatory drugs increase the risk of bleeding in patients with gastroduodenal ulcer. Dig Dis Sci 2015;60:1010–1015.
    1. Lin KJ, De Caterina R, García Rodríguez LA. Low‐dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population‐based, nested case‐control study. Circ Cardiovasc Qual Outcomes 2014;7:70–77.
    1. Hirata Y, Kataoka H, Shimura T, Mizushima T, Mizoshita T, Tanida S, Kamiya T, Joh T. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric‐coated aspirin. Scand J Gastroenterol 2011;46:803–809.
    1. Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol 2012;156:69–75.
    1. Moberg C, Naesdal J, Svedberg LE, Duchateau D, Harte N. Impact of gastrointestinal problems on adherence to low‐dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. Patient 2011;4:103–113.
    1. Pratt S, Thompson VJ, Elkin EP, Næsdal J, Sörstadius E. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low‐dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs 2010;10:281–288.
    1. Derogar M, Sandblom G, Lundell L, Orsini N, Bottai M, Lu Y, Sadr‐Azodi O. Discontinuation of low‐dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin Gastroenterol Hepatol 2013;11:38–42.
    1. García Rodríguez LA, Cea‐Soríano L, Martín‐Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case‐control study in UK primary care. Br Med J 2011;343:d4094.
    1. García Rodríguez LA, Cea‐Soríano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011;76:740–746.
    1. Biondi‐Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta‐analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667–2674.
    1. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Am J Gastroenterol 2008;103:2890–2907.
    1. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Am J Gastroenterol 2010;105:2533–2549.
    1. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low‐dose aspirin. Best Pract Res Clin Gastroenterol 2012;26:125–140.
    1. Thorat MA, Cuzick J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol 2015;30:5–18.
    1. Weil J, Colin‐Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827–830.
    1. Laine L. Review article: gastrointestinal bleeding with low‐dose aspirin – what's the risk? Aliment Pharmacol Ther 2006;24:897–908.
    1. Valkhoff VE, Sturkenboom MC, Hill C, Veldhuyzen van Zanten S, Kuipers EJ. Low‐dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: a meta‐analysis of randomized clinical trials and observational studies. Can J Gastroenterol 2013;27:159–167.
    1. De Jong HJ, Korevaar JC, van Dijk L, Voogd E, van Dijk CE, van Oijen MG. Suboptimal prescribing of proton‐pump inhibitors in low‐dose aspirin users: a cohort study in primary care. BMJ Open 2013;3:e003044. doi:1136/bmjopen‐2013‐003044.
    1. Morneau KM, Reaves AB, Martin JB, Oliphant CS. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel. J Manag Care Pharm 2014;20:187–193.
    1. Casado‐Arroyo R, Scheiman JM, Polo‐Tomas M, Saini SD, Del Rio A, Guastello E, Lanas A Underutilization of gastroprotection for at‐risk patients undergoing percutaneous coronary intervention: Spain compared with the United States. Aliment Pharmacol Ther 2010;32:689–695.
    1. Targownik LE, Metge CJ, Leung S. Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Aliment Pharmacol Ther 2008;28:88–96.
    1. Elnachef N, Scheiman JM, Fendrick AM, Howden CW, Chey WD. Changing perceptions and practices regarding aspirin, nonsteroidal anti‐inflammatory drugs, and cyclooxygenase‐2 selective nonsteroidal anti‐inflammatory drugs among US primary care providers. Aliment Pharmacol Ther 2008;28:1249–1258.
    1. Bytzer P, Pratt S, Elkin E, Næsdal J, Sörstadius E. Burden of upper gastrointestinal symptoms in patients receiving low‐dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study. Am J Cardiovasc Drugs 2013;13:27–35.
    1. Hedberg J, Sundström J, Thuresson M, Aarskog P, Oldgren J, Bodegard J. Low‐dose acetylsalicylic acid and gastrointestinal ulcers or bleeding–a cohort study of the effects of proton pump inhibitor use patterns. J Intern Med 2013;274:371–380.
    1. Warlé‐van Herwaarden MF, Koffeman AR, Valkhoff VE, ‘t Jong GW, Kramers C, Sturkenboom MC, De Smet PA. Time‐trends in the prescribing of gastroprotective agents to primary care patients initiating low‐dose aspirin or non‐steroidal anti‐inflammatory drugs: a population based cohort study. Br J Clin Pharmacol 2015;80:589–598.
    1. van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID‐related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007;26:265–275.
    1. Henriksson K, From J, Stratelis G. Patient‐reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti‐inflammatory drugs. Patient Prefer Adher 2014;8:1611–1617.
    1. Valkhoff VE, van Soest EM, Mazzaglia G, et al. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population‐based study. Arthritis Rheum 2012;64:2792–2802.
    1. van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011;60:1650–1659.
    1. Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP. Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther 2009;30:767–774.
    1. Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal‐related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337–1345.
    1. Massó González EL, García Rodríguez LA. Proton pump inhibitors reduce the long‐term risk of recurrent upper gastrointestinal bleeding: an observational study. Aliment Pharmacol Ther 2008;28:629–637.
    1. Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric‐coated aspirin 325 mg + immediate‐release omeprazole 40 mg) or enteric‐coated aspirin 325 mg + enteric‐coated omeprazole 40 mg – a randomised, phase 1, crossover study. Aliment Pharmacol Ther 2013;38:62–71.
    1. Whellan DJ, Goldstein JL, Cryer BL, et al. PA32540 (a coordinated‐delivery tablet of enteric‐coated aspirin 325 mg and immediate‐release omeprazole 40 mg) versus enteric‐coated aspirin 325 mg alone in subjects at risk for aspirin‐associated gastric ulcers: Results of two, 6‐month, phase 3 studies. Am Heart J 2014;168:495–502.
    1. Catella‐Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809–1817.
    1. Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs. Aliment Pharmacol Ther 2003;18:1137–1147.
    1. Verdickt W, Moran C, Hantzschel H, Fraga AM, Stead H, Geis GS. A double‐blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992;21:85–91.
    1. Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen alone. Aliment Pharmacol Ther 2010;32:401–413.
    1. Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double‐blind randomized trials of single‐tablet ibuprofen/high‐dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379–386.
    1. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low‐dose aspirin. Am J Gastroenterol 2008;103:2465–2473.
    1. Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, et al. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low‐dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol 2013;61:250–257.
    1. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low‐dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 2011;97:797–802.
    1. Martín Merino E, Johansson S, Nagy P, García Rodríguez LA. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United Kingdom primary care. Am J Cardiol 2013;112:1075–1082.
    1. Saini SD, Fendrick AM, Scheiman JM. Cost‐effectiveness analysis: cardiovascular benefits of proton pump inhibitor co‐therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther 2011;34:243–251.
    1. Singh G, Mannalithara A, Arora A, Mithal A, Triadafilopoulos G. Concomitant proton pump inhibitor therapy improves adherence in low‐dose aspirin users: a community‐based study. Eur Heart J 2011;32(abstract suppl.):416.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren